Neue cholesterinsenkende Pille senkt den schlechten Cholesterinspiegel um fast 60 %

„The drug, called Enlicitide and developed by Merck, is a new type of PCSK9 inhibitor. It works by binding to PCSK9, a blood protein that typically degrades the liver receptors that clear LDL cholesterol. By blocking PCSK9, Enlicitide protects these receptors and boosts the liver’s ability to clear LDL cholesterol from the bloodstream, lowering the risk of heart disease.“